SiSaf is a young, commercial-stage drug development company with offices in the UK and the United States. We are pioneers of bio-courier technology, a novel method of drug delivery offering exceptional safety and versatility. We reformulate approved drug molecules with known limitations to make them more effective. We also develop formulations for clients, our own subsidiaries and grant-funded R&D projects.
To date, SiSaf and its unique technology have attracted close to $3m in grant funding and over $14m of equity investment.